Skip to main content
TipRanks
Go Ultimate75% OFF

Novavax (NVAX) Stock Price & Analysis

10,192 Followers

NVAX Stock Chart & Stats

$7.96-$0.10(-1.24%)
At close: 4:00 PM EST
$8$10$12Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$7.88 - $8.14
52-Week Range
$6.20 - $13.39
Previous Close
$8.06
Volume
N/A
Average Volume (3M)
6.96M
Market Cap
$1.31B
Enterprise Value
$1.46B
Total Cash (Recent Filing)
$622.36M
Total Debt (Recent Filing)
$295.26M
Price to Earnings (P/E)
―
Beta
1.59
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sanofi Partnership Monetization

The Sanofi alliance provides Novavax with meaningful non-product revenue, milestone potential, and validation from a major vaccine partner. Additional technology-transfer and commercial-launch milestones, plus royalties, could support funding and diversify commercialization beyond standalone COVID vaccine sales.

Validated Matrix-M Platform

Matrix-M has progressed beyond a single experimental application into two commercial vaccines, demonstrating real-world platform utility and scale. That validation can improve partner interest, support licensing or supply opportunities, and create longer-term optionality across infectious-disease programs.

Cost Reduction And Cash Runway

Planned operating-cost reductions could materially lower the spending base and extend financial flexibility, while the stated runway reduces near-term financing pressure. If executed, the restructuring may allow Novavax to focus resources on commercial products, partnerships, and selected pipeline opportunities.

Bears Say

Volatile And Declining Revenue

The sharp reversal in revenue and earnings indicates that Novavax has not yet established a stable commercial scale. Such volatility makes planning and investment more difficult, while renewed losses can limit internally funded development and increase reliance on milestones or other external revenue sources.

Negative Shareholders’ Equity

A persistently negative equity base is a structural balance-sheet weakness rather than a temporary earnings fluctuation. It reduces financial resilience, makes leverage measures less favorable, and leaves less capacity to absorb setbacks or fund strategic initiatives without depending on operating improvement or partner-related cash inflows.

Persistent Cash Burn

Ongoing negative operating and free cash flow shows that the business is not currently self-funding its operations. Even with a stated cash runway, continued outflows increase dependence on milestones, product demand, cost reductions, or financing alternatives to sustain development and commercial activities over time.

Novavax News

NVAX FAQ

What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $6.20 and its highest was $13.39 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.31B.
When is Novavax’s upcoming earnings report date?
Novavax’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 105 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 05, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.156.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is 0.54.
How many shares outstanding does Novavax have?
Novavax has 165,009,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went down -8.169%.
Which hedge fund is a major shareholder of Novavax?
Hedge funds hold Novavax shares: the largest hedge-fund position in Novavax is 72,325,942 shares, and hedge funds increased their holdings by 1.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology